HRP20030928A2 - Adenosine analogues for the treatment of the insulin resistance syndrome and diabetes - Google Patents

Adenosine analogues for the treatment of the insulin resistance syndrome and diabetes

Info

Publication number
HRP20030928A2
HRP20030928A2 HR20030928A HRP20030928A HRP20030928A2 HR P20030928 A2 HRP20030928 A2 HR P20030928A2 HR 20030928 A HR20030928 A HR 20030928A HR P20030928 A HRP20030928 A HR P20030928A HR P20030928 A2 HRP20030928 A2 HR P20030928A2
Authority
HR
Croatia
Prior art keywords
diabetes
treatment
insulin resistance
resistance syndrome
adenosine analogues
Prior art date
Application number
HR20030928A
Other languages
English (en)
Inventor
Herling Andreas
Jaehne Gerhard
P. Maguire Martin
P. Spada Alfred
R. Myers Michael
Mi Choi-Sledeski Yong
W. Pauls Heinz
R. Ewing William
Original Assignee
Aventis Pharma Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh
Publication of HRP20030928A2 publication Critical patent/HRP20030928A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
HR20030928A 2001-05-14 2002-05-14 Adenosine analogues for the treatment of the insulin resistance syndrome and diabetes HRP20030928A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01111651A EP1258247A1 (en) 2001-05-14 2001-05-14 Adenosine analogues for the treatment of insulin resistance syndrome and diabetes
PCT/EP2002/005301 WO2002092093A1 (en) 2001-05-14 2002-05-14 Adenosine analogues for the treatment of the insulin resistance syndrome and diabetes

Publications (1)

Publication Number Publication Date
HRP20030928A2 true HRP20030928A2 (en) 2005-10-31

Family

ID=8177414

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030928A HRP20030928A2 (en) 2001-05-14 2002-05-14 Adenosine analogues for the treatment of the insulin resistance syndrome and diabetes

Country Status (23)

Country Link
US (1) US20030176390A1 (cs)
EP (2) EP1258247A1 (cs)
JP (1) JP2004533448A (cs)
KR (1) KR20040002962A (cs)
CN (1) CN1518450A (cs)
BG (1) BG108356A (cs)
BR (1) BR0209650A (cs)
CA (1) CA2447408A1 (cs)
CO (1) CO5540288A2 (cs)
CZ (1) CZ20033079A3 (cs)
EA (1) EA007253B1 (cs)
EE (1) EE200300551A (cs)
HR (1) HRP20030928A2 (cs)
HU (1) HUP0400464A3 (cs)
IL (1) IL158794A0 (cs)
MX (1) MXPA03010336A (cs)
NO (1) NO20035056D0 (cs)
NZ (1) NZ529390A (cs)
PL (1) PL364573A1 (cs)
SK (1) SK14052003A3 (cs)
WO (1) WO2002092093A1 (cs)
YU (1) YU90203A (cs)
ZA (1) ZA200308777B (cs)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607948D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
PT2013211E (pt) * 2006-04-21 2012-06-21 Novartis Ag Derivados de purina para utilização como agonistas de receptores a2a de adenosina
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
KR20090087054A (ko) * 2006-11-10 2009-08-14 노파르티스 아게 시클로펜텐 디올 모노아세테이트 유도체
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009131196A1 (ja) * 2008-04-24 2009-10-29 武田薬品工業株式会社 置換ピロリジン誘導体およびその用途
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN119798352A (zh) * 2024-01-15 2025-04-11 中国医学科学院药物研究所 化合物yzg-331的晶型及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8729994D0 (en) * 1987-12-23 1988-02-03 Glaxo Group Ltd Chemical compounds
US5055569A (en) * 1989-10-19 1991-10-08 G. D. Searle & Co. N-(6)-substituted adenosine compounds
HUT61567A (en) * 1990-12-07 1993-01-28 Sandoz Ag Process for producing new pharmaceutical compositions comprising 2'-o-alkyladenosine derivatives and for producing 6-cyclohexyl-2'-o-methyladenosinehydrate
UA51716C2 (uk) * 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
US6376472B1 (en) * 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
US6258793B1 (en) * 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives

Also Published As

Publication number Publication date
HUP0400464A2 (hu) 2004-07-28
EP1404338A1 (en) 2004-04-07
BR0209650A (pt) 2004-07-13
CN1518450A (zh) 2004-08-04
CZ20033079A3 (cs) 2004-08-18
SK14052003A3 (sk) 2004-07-07
EA007253B1 (ru) 2006-08-25
EA200301231A1 (ru) 2004-04-29
WO2002092093A1 (en) 2002-11-21
NZ529390A (en) 2006-06-30
KR20040002962A (ko) 2004-01-07
PL364573A1 (en) 2004-12-13
MXPA03010336A (es) 2004-03-16
JP2004533448A (ja) 2004-11-04
EE200300551A (et) 2004-02-16
NO20035056D0 (no) 2003-11-13
EP1258247A1 (en) 2002-11-20
US20030176390A1 (en) 2003-09-18
CO5540288A2 (es) 2005-07-29
YU90203A (sh) 2006-08-17
CA2447408A1 (en) 2002-11-21
BG108356A (bg) 2004-12-30
ZA200308777B (en) 2006-04-26
IL158794A0 (en) 2004-05-12
HUP0400464A3 (en) 2007-03-28

Similar Documents

Publication Publication Date Title
IL161155A0 (en) Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
ZA200402688B (en) Method and composition for preventing or reducing the symptons of insulin resistance syndrome.
HUP0203367A3 (en) Benzylidine-thiazolidinediones and analogues and their use in the treatment of diabetes
AU2003272658A8 (en) Orthopedic medical device with unitary components
HRP20030928A2 (en) Adenosine analogues for the treatment of the insulin resistance syndrome and diabetes
AP2003002918A0 (en) Pulmonary administration of chemically modified insulin.
PL372865A1 (en) Aryl 5-thio-beta-d-glucopyranoside derivatives and remedies for diabetes containing the same
IL218909A0 (en) Treatment of diabetes
AU2002345544A8 (en) Method of immobilizing a biologic in a polyurethane-hydrogel composition, a composition prepared from the method, and biomedical applications
HUP0300725A3 (en) Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors
PL1623228T3 (pl) APOCIII i leczenie oraz diagnozowanie cukrzycy
AU2003279442A8 (en) 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
AU2001256373A1 (en) Syringe and method for the use thereof
EP1575582A4 (en) COMBINED THERAPY FOR THE TREATMENT OF ACUTE LEUKEMIA AND MYELODYSPLASIC SYNDROME
AU2003252182A8 (en) Therapeutic treatment for the metabolic syndrome and type 2 diabetes
AU2003255612A8 (en) Novel multimeric molecules, the preparation method thereof and use of same for the preparation of medicaments
IL164951A0 (en) The treatment of pain with lfendropil
GB0212790D0 (en) Medicament for the treatment of diabetes
GB0117134D0 (en) Treatment of the insulin resistance syndrome
GB0106465D0 (en) Treatment of the insulin resistance syndrome
GB0030649D0 (en) Treatment of the insulin resistance syndrome
GB0024093D0 (en) Treatment of the insulin resistance syndrome
PL369309A1 (en) Modified insulin with reduced immunogenicity
AU2003273192A8 (en) Compounds and compositions for the treatment of diabetes and diabetes-related disorders
ZA200301030B (en) Treatment of the insulin resistance syndrome.

Legal Events

Date Code Title Description
A1OB Publication of a patent application
PNAN Change of the applicant name, address/residence

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, DE

ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
OBST Application withdrawn